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Abstract 
Objective In statin-treated patients with stable coronary artery disease (CAD), residual risk of 
cardiovascular events is partly explained by plasma levels of low-density lipoprotein cholesterol (LDL-C). 
This study aimed to estimate individual benefit of proprotein convertase subtilisin/kexin type 9 (PCSK9) 
inhibition in CAD patients already treated with high-dose statin. 
Methods Individual lifetime benefit was estimated in months gain free of stroke or myocardial infarction 
(MI) until age 80. Predictions were based on two competing risk models developed in data from 4,853 
patients with CAD originating from the atorvastatin 80 mg arm of the Treating to New Targets (TNT) trial. 
The relative effect of PCSK9-inhibition was added to the models and was assumed based on average 
estimates from large clinical trials. We accounted for individual LDL-C levels, assuming 50% LDL-C 
reduction by PCSK9-inhibition and 21% cardiovascular risk reduction per mmol/L (39 mg/dL) LDL-C 
lowering.   
Results Estimated individual gain was <6 months in 61% of the patients, 6-12 months in 28% of the patients, 
and ≥12 months in 10% of the patients (median 5, quartiles 2-8 months). Highest estimated benefit was 
observed in younger patients (aged 40-60) with high risk factor burden, particularly if LDL-C levels were 
>1.8 mmol/L (>70 mg/dL). Estimated benefit was lowest (≤5 months) in older patients (≥70 years), in 
particular if LDL-C and other risk factors levels were low. 
Conclusion The individual estimated lifetime benefit from PCSK9-inhibition in patients with stable CAD 
on high-dose statin varied from <6 to ≥12 months free of stroke or MI. Highest benefit is expected in 
younger patients (age 40-60) with high risk factor burden and relatively high LDL-C levels. 
Keywords Individual benefit, lifetime, PCSK9-inhibition, lipid lowering, CAD 
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KEY MESSAGES 
What is already known about this subject? 
In statin-treated patients with stable coronary artery disease, residual risk of cardiovascular events is partly 
explained by plasma levels of LDL-C. With the availability of highly effective but expensive PCSK9-
inhibitors, there is a need to identify individual patients who will benefit most from this additional lipid-
lowering treatment. 
 
What does this study add? 
The present study shows the great interpersonal variation in estimated benefit from PCSK9-inhibition in 
patients with stable coronary artery disease on high-dose statin, ranging from <6 months to ≥12 months free 
of stroke or myocardial infarction. Highest benefit is expected in younger patients (age 40-60) with a high 
risk factor burden and relatively high LDL-C levels. 
 
How might this impact on clinical practice? 
These findings may contribute to the discussion which patients with stable coronary artery disease should 
be eligible for treatment with PCSK9-inhibition. Also, individualized estimation of treatment benefit can be 
used to inform the patient and contribute to shared decision making on whether or not initiating PCSK9-
inhibition on individual patient level.  
 
  
Introduction 
Patients with stable coronary artery disease (CAD) are at risk for developing new major adverse 
cardiovascular events (i.e. myocardial infarction (MI), stroke, or cardiovascular death), despite 
optimal secondary prevention according to guidelines.1-3 This residual risk is partly explained by 
low-density lipoprotein cholesterol (LDL-C) levels, even when on high-dose statin therapy.1 
Recently, results from the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in 
Subjects with Elevated Risk (FOURIER) trial have shown that Proprotein convertase 
subtilisin/kexin type 9 (PCSK9)-inhibitors attenuate residual risk by substantial additional LDL-C 
reductions.4 Currently, clinicians face the dilemma which patients should be treated with these 
effective but costly agents.5  
An estimation of the anticipated effectiveness derived by PCSK9-inhibition for individual patients 
can be extrapolated from the expected lipid lowering effect obtained through PCSK9-inhibition 
(50-60%)6 and the robust relationship between LDL-C reduction and cardiovascular events (HR 
0.79 per 1.0 mmol/L LDL-C (or per 39 mg/dL)), which was observed for both statins and ezetimibe, 
and more recently in the FOURIER study also for PCSK9-inhibition by evolocumab.4, 7, 8 This 
information can be incorporated in recently developed methods to estimate cardiovascular 
prognosis in individual patients with cardiovascular disease in order to estimate individualized 
benefit from PCSK9-inhibition.9-12 
In the present study we aimed to estimate individual benefit of PCSK9-inhibition in patients with 
stable CAD on high-dose statin therapy originating from the Treating to New Targets (TNT) trial.13 
As preventive treatment is often continued lifelong, individual benefit was estimated from a 
lifetime perspective and expressed in terms of gain in life expectancy free of (recurrent) stroke or 
MI.  
Methods 
Study population 
The design and results of the TNT trial have previously been published.13, 14 TNT was an 
international clinical trial that enrolled 10,001 men and women aged 35-75 with stable CAD 
(previous MI, angina with evidence of atherosclerotic coronary disease, or previous coronary 
revascularization) who had LDL-C levels <3.4 mmol/L (<130 mg/dL)) after an open-label 8-week 
run-in period with atorvastatin 10 mg. Patients were randomized to either atorvastatin 80 or 10 mg 
daily. For the present analysis, we selected patients aged>40 years allocated to the atorvastatin 80 
mg arm. We used the three-month on-treatment visit as starting point, when participants were in 
steady state on statin treatment. Covariate data were missing on 1% or less of participants and were 
reduced by single imputation using predictive mean matching (aregImpute-algorithm in R, Hmisc-
package) based on other patient characteristics and outcomes.15 The TNT trial complied with the 
Declaration of Helsinki, approval was obtained from institutional review boards and all participants 
provided written informed consent. 
 
Individual benefit 
Individual benefit from PCSK9-inhibition in addition to high-dose statins was estimated based on: 
1) Individual relative risk reduction, which estimate was derived from large clinical trial data and 
dependent on an individual’s LDL-c level; and 2) Individual cardiovascular disease prognosis, 
which was estimated based on two competing risk models that were derived from individual patient 
data from the TNT trial. 
Individual relative risk reduction 
An individual’s relative effect of PCSK9-inhibition was based on the expected LDL-C reduction, 
which is conditional to the baseline LDL-C level (i.e. on statin therapy).8, 16 On average, PCSK9-
inhibitors reduce LDL-C levels by 50-60%.6, 17 To prevent overoptimistic estimates of treatment 
benefit, we assumed a 50% LDL-C reduction in the present study. Large meta-analyses have shown 
a hazard ratio of 0.79 for major cardiovascular events per mmol/L (39 mg/dL) LDL-C reduction 
and the results of the FOURIER trial confirm that the effect of PCSK9-inhibition is in line with 
this.4, 8 Thus, an individualized relative effect of PCSK9-inhibition was defined as 0.790.5*LDL-C. 
Such individualized hazard ratios were calculated for each study participant. We assumed no effect 
of PCSK9-inhibitors on non-cardiovascular mortality (i.e. relative risk of 1).8 
Individual cardiovascular disease prognosis 
Generally applied methods to estimate major cardiovascular events (e.g. Cox proportional hazard 
models) assume that when a patient is censored, the patient remains at risk of the event of interest, 
whilst in reality the patient may also have died from something else (i.e. non-cardiovascular 
mortality). Using such methods may result in overestimation of risk for the event of interest, in 
particular in the setting of lifetime predictions. Therefore, to allow lifetime prediction modeling, 
we used Fine and Gray competing risk models that account for competing events. These methods 
were described in detail previously.10, 18, 19 In short, we developed two competing risk models for 
cause-specific cumulative incidence, one for major cardiovascular events (stroke, MI or 
cardiovascular death) and one for non-cardiovascular mortality. We used age as the underlying 
time function, which allowed us to make lifetime predictions across the age range from the 
youngest age at study entry to the highest age at study exit. Risk factors in this model were pre-
specified and based on a previous risk score in cardiovascular patients and the availability of 
predictors in TNT.9 As a result, both models contained the following nine predictors: sex, current 
smoking, diabetes mellitus, systolic blood pressure (mmHg), total cholesterol (mmol/L), eGFR 
(MDRD) squared (umol/L), history of cerebrovascular disease, history of peripheral artery disease, 
history of abdominal aortic aneurysm. Pre-specified predictors (including the squared terms for 
eGFR) were chosen as this is likely to increase the external validity of the model compared to a 
newly developed best fit model.20 The calculation of lifetime estimates has been described in detail 
previously.18, 19 Summarized, beginning at the starting age of each individual, the cumulative 
survival free of stroke or MI was estimated for each subsequent year. Therefore, the estimated 
survival free of stroke and MI at the beginning of each life-year was multiplied by the survival 
probability during that year. The survival probability was obtained by subtracting cardiovascular 
risk and non-cardiovascular mortality risk (estimated with the cardiovascular model and the non-
cardiovascular mortality model respectively) from 1. This was repeated until the age of 80 as there 
were few observations beyond this age. Continuous predictors were truncated at the 1st and 99th 
percentile to limit the effect of outliers. The proportional hazards assumption of both models was 
assessed by testing the correlations between scaled Schoenfeld residuals for each predictor and age.  
 
Estimation of individual absolute treatment benefit  
Subsequently, the prediction model was used to estimate for each study patient 10-year risk of 
stroke, MI or cardiovascular death, and survival free of (recurrent) stroke or MI until age 80 (later 
referred to as lifetime prediction). The added effect of PCSK9-inhibition on survival was estimated 
by adding the estimated individual relative risk reductions as a coefficient in the competing-risk 
adjusted model. Individual’s treatment benefit was defined as the estimated improvement of each 
survival parameter and expressed in months gain in life expectancy free of (recurrent) stroke or 
MI. In order to draw 95% prediction intervals around individual treatment benefit estimations, 
these analyses were repeated in 1000 bootstrap samples from which 95% prediction intervals were 
derived.  
 
Sensitivity analyses 
In TNT, patients were not treated with ezetimibe. It is however common practice to first add 
ezetimibe before considering PCSK9-inhibition. Therefore, we performed a sensitivity analysis 
assuming patients were on both high-dose statin and ezetimibe before the initiation of PCSK9-
inhibition. We assumed 24% LDL-C reduction by ezetimibe21 and an HR of 0.79 cardiovascular 
risk reduction per 1.0 mmol/L (39 mg/dL) LDL-C lowering.  
In a second sensitivity analysis we assumed a lower adherence rate to PCSK9-inhibition. Instead 
of an adherence rate of 87.5% as observed in the FOURIER trial,4 an adherence of 50% was 
assumed which is generally reported for preventive cardiovascular medication.22 This resulted in 
29% (compared to 50%) LDL-C reduction (50%/87.5%*50% LDL-C reduction). 
 
 
Results 
Table 1 shows the characteristics of the study population (n=4,853). On average, patients were 61 
(±SD 9) years old and 81% were male. More than half of the patients (59%) had a history of MI. 
In addition to CAD, 5% of the patients had a history of cerebrovascular disease (transient ischemic 
attack or stroke) and 12% had a history of peripheral artery disease. LDL-C levels on atorvastatin 
80 mg were on average 1.9 (±SD 0.6) (73 mg/dL ±SD 23) mmol/L and residual 10-year estimated 
risk ranged from <10% in 30% to >30% in 3% of the patients (Supplemental Figure 1). 
Table 1. Patient characteristics 
  
TNT participants on 
atorvastatin 80 mg 
  (n = 4,853) 
    
Age (years) 61 (9) 
Age <50 years 551 (11%) 
Age 50-60 years 1,486 (31%) 
Age 60-70 years 1,928 (40%) 
Age ≥70 years 888 (18%) 
Male sex 3,929 (81%) 
Smoking status 635 (13%) 
Diabetes mellitus 740 (15%) 
Body mass index (kg/m2) 28 (4) 
Systolic blood pressure (mmHg) 131 (17) 
Diastolic blood pressure (mmHg) 78 (9) 
Antihypertensive therapy 3,872 (80%) 
Aspirin  4,212 (87%) 
    
Total cholesterol (mmol/L) 3.8 (0.7) 
LDL-cholesterol (mmol/L) 1.9 (0.6) 
HDL-cholesterol (mmol/L) 1.2 (0.3) 
eGFR (MDRD) (mL/min/1.73m2) 65 (11) 
    
Cardiovascular history   
   Myocardial infarction 2,855 (59%) 
   Coronary artery bypass grafting 2,261 (47%) 
   Cerebrovascular disease  247 (5%) 
   Peripheral artery disease  590 (12%) 
   Abdominal aortic aneurysm 86 (2%) 
   Congestive heart failure 360 (7%) 
    
All data are displayed as mean (standard deviation) or  
number (percentage) 
 
Individual benefit of PCSK9-inhibition 
The median estimated lifetime benefit from initiating PCSK9-inhibition was 5 months (IQR 2-8) 
and varied substantially (Figure 1), ranging from <6 months in 61% of the patients to>12 months 
in 10% of the patients. Table 2 shows patient characteristics stratified for estimated benefit. Patients 
with highest estimated benefit (≥12 months) were younger (mean age 50 years ±SD 6), had higher 
LDL-C levels (mean 2.4 mmol/L ±SD 0.7 (93 mg/dL ±SD 27)) and risk factors were more 
prevalent, i.e. more smokers, diabetes compared to patients with lowest estimated benefit (<6 
months) with a mean age of 66 years (±SD 6 years) and an average LDL-C level of 1.8 mmol/L 
(±SD 0.5 mmol/L) (70 mg/dL ±SD 19). Table 3 shows median expected benefit for subgroups of 
several combinations of age, LDL-C level and estimated 10-year cardiovascular risk. Highest 
benefit was seen in middle-aged patients (age 40-60 years), in particular if LDL-C levels were >1.8 
mmol/L (>70 mg/dL). Treatment benefits truncated after the first 10 years of treatment turned out 
to be similar across different age groups (≤8 months). However, the model estimated more benefit 
in younger patients and those with higher risk and higher LDL-C levels based on 20-year or lifelong 
predictions.  
Supplemental Tables 1 and 2 show the coefficients and age-specific baseline survivals of both the 
cardiovascular and non-cardiovascular death competing risk models. The proportional hazard 
assumption was met for the cardiovascular event model. In the non-cardiovascular death model, 
non-proportionality was observed for current smoking. Therefore, an interaction between age and 
smoking status was included in this model. Supplemental Figure 2 shows the agreement between 
the predicted and observed survivals free of stroke or MI in the study population. 
 
Table 2. Baseline characteristics stratified for benefit from lifelong PCSK9-
inhibition in terms of months gain free of stroke or MI 
  
<6 months 
gain 
6-12 months 
gain 
≥12 months 
gain 
  (n = 2,957) (n = 1,323) (n = 461) 
        
Age (years) 66 (6) 55 (6) 50 (6) 
Male sex 2,274 (77%) 1,150 (87%) 425 (92%) 
Smoking status 204 (7%) 259 (20%) 170 (37%) 
Diabetes mellitus 385 (13%) 222 (17%) 108 (23%) 
Body mass index (kg/m2) 28 (4) 29 (5) 30 (5) 
Systolic blood pressure (mmHg) 131 (17) 129 (16) 129 (16) 
Diastolic blood pressure (mmHg) 77 (9) 79 (9) 80 (10) 
Antihypertensive therapy 2,366 (80%) 1,048 (79%) 363 (79%) 
Aspirin  2,568 (87%) 1,167 (88%) 388 (84%) 
        
Total cholesterol (mmol/L) 3.6 (0.6) 3.9 (0.7) 4.3 (0.8) 
LDL-cholesterol (mmol/L) 1.8 (0.5) 2.0 (0.5) 2.4 (0.7) 
HDL-cholesterol (mmol/L) 1.3 (0.3) 1.2 (0.3) 1.1 (0.2) 
eGFR (MDRD) (mL/min/1.73m2) 63 (10) 67 (11) 71 (12) 
        
Cardiovascular history       
   Myocardial infarction 1,673 (57%) 808 (61%) 308 (67%) 
   Coronary artery bypass grafting 1,435 (49%) 583 (44%) 176 (38%) 
   Cerebrovascular disease  116 (4%) 74 (6%) 49 (11%) 
   Peripheral artery disease  306 (10%) 181 (14%) 73 (16%) 
   Congestive heart failure 203 (7%) 104 (8%) 36 (8%) 
        
Estimated 10-year risk of stroke, 
MI or vascular death (%) 11 (9-15) 12 (10-16) 16 (13-20) 
        
All data are displayed as mean (standard deviation), median (interquartile range) or 
number (percentage). 
 
  
Table 3. Estimated individual gain of PCSK9-inhibition in months free of (recurrent) stroke or MI during lifelong, 20-year or 
10-year treatment
Initiation age ≥70
Lifetime 20 years 10 years Lifetime 20 years 10 years 20 years 10 years 10 years
Risk <10%
LDL<1.8 8 3 1 5 3 1 2 1 0
LDL 1.8-2.6 10 4 1 7 4 1 3 1 1
LDL ≥2.6 14 6 2 9 6 2 4 2 1
Risk 10-20%
LDL<1.8 10 4 1 7 5 1 3 1 1
LDL 1.8-2.6 15 6 2 10 6 2 4 2 1
LDL ≥2.6 22 9 2 14 9 3 5 3 2
Risk 20-30%
LDL<1.8 15 6 2 10 8 2 5 2 2
LDL 1.8-2.6 22 10 3 15 10 3 7 3 2
LDL ≥2.6 34 13 4 19 14 4 9 5 4
Risk >30%
LDL<1.8 21 11 4 12 10 4 7 3 2
LDL 1.8-2.6 23 11 4 16 13 5 9 5 3
LDL ≥2.6 NA NA NA 32 22 8 16 7 5
Initiation age ≥40-<50 Initiation age ≥50-<60 Initiation age ≥60-<70
Median values were shown based on the estimates in the study population. NA means there were no or only one patients in the study population 
with this combination of characteristics to derive a reliable median. Importantly, expected benefit is also determined by a patient’s risk of other 
causes of mortality. For the individual patient, expected benefit should thus be estimated using a calculator and should not be derived from this 
table. NOTE: as treatment effects were truncated at age 80, in patients aged >= 70, the lifetime, 20-year and 10-year predictions are similar. 
Therefore, only 10-year predictions were shown. For patients aged 60-70, the lifetime and 20-year predictions are similar. Therefore, only 20-year 
and 10-year predictions were shown.  The subgroup of patients aged >=70 consists of patients aged 70-75 due to inclusion inclusion criteria.
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Individual benefit of PCSK9-inhibition: case illustrations 
Patient A is 40 years old and has an estimated 10-year cardiovascular risk of 10% and an LDL-C 
of 1.8 mmol/L (70 mg/dL) (Figure 2). His estimated gain from lifelong PSCK9-inhibition is 14 
months free of (recurrent) stroke or MI (95% prediction interval (PI) 10-20 months), counting only 
a first recurrent event. For patient E with similar estimated risk and residual LDL-C level but aged 
70, this gain would be only 1 month (95%-PI 1-2). Due to her higher age, patient E has shorter 
remaining life expectancy in which she can benefit from treatment and reduction of cardiovascular 
event risk will be counterbalanced by competing risks due to non-cardiovascular mortality. If these 
patients had higher LDL-C levels, i.e. 3.0 mmol/L (116 mg/dL), this would result in higher lifetime 
benefits of 22 (95%-PI 16-32) months (patient B) and 2 (95%-PI 1-3) months (patient F). The right 
part of Figure 2 shows examples of high-risk patients, i.e. 25% 10-year risk. Compared to low-risk 
patients, i.e. 10% 10-year cardiovascular risk, high-risk patients have higher estimated treatment 
benefit. 
 
Sensitivity analyses 
The estimated benefit from PCSK9-inhibition when added to statin/ezetimibe combination therapy 
is less compared to the benefit when added to statin monotherapy (Supplemental Table 3) with a 
median estimated lifetime benefit of 3 months (IQR 2-6), ranging from < 6 months in 76% to >12 
months in 4% of the patients. The sensitivity analysis assuming 50% (instead of 87.5%) adherence 
rate showed a median estimated benefit of 3 months (IQR 1-5 months), ranging from <6 months in 
83% to >12 months in 2% of the patients (Supplemental Table 4). 
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Discussion 
In the present study we estimated individual benefit from PCSK9-inhibition in terms of months 
gained free of (recurrent) stroke or MI in statin-treated patients with stable CAD. There was 
substantial variation in individual estimated benefit ranging from less than 6 months in 61% of the 
patients to more than 12 months in 10% of patients. On average, estimated lifetime benefit was 
highest if treatment is initiated in younger patients (aged 40-60) with relatively high risk factor 
levels and particularly if LDL-C levels were >1.8 mmol/L (>70 mg/dL). 
 
Which patients should be eligible for costly lipid lowering therapy with PCSK9-inhibitors is much 
debated. Intuitively, clinicians may tend to select patients for PCSK9-inhibition based on level of 
cardiovascular risk, e.g. patients with cardiovascular disease at multiple locations, or high 
estimated 10-year risk based on a risk algorithm. Indeed, in the first years after starting treatment 
this may result in slightly higher treatment benefit than selecting lower risk patients (Table 3). 
However, as preventive treatment is often continued lifelong, it is more relevant to estimate benefit 
from a lifetime perspective. Moreover, age itself is an important cardiovascular risk factor as it 
represents exposure time. Therefore, a short-term high-risk-based approach generally leads to 
selecting older patients for treatment (generally >60 years of age).19 This approach has been 
questioned, as many patients develop clinically manifest cardiovascular disease before the age of 
60.23  The present study shows that indeed a risk-based approach may result in suboptimal treatment 
decisions, as greatest benefit can be achieved by starting treatment in middle-aged patients (aged 
40-60) in particular if LDL-C levels are >1.8 mmol/L (>70 mg/dL) (Table 2 and 3). This is 
explained by the longer life expectancy in which these patients can benefit from therapy. In older 
patients (>70 years), the estimated benefit was limited, in particular if levels of LDL-C and other 
cardiovascular risk factor were low. Importantly, if ezetimibe is added before initiation of PCSK9-
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inhibition, anticipated treatment benefits are somewhat lower for all subgroups (Supplemental 
Table 3). Also, lower adherence rates will result in lower treatment benefits (Supplemental Table 
4). 
 
What amount of benefit can be considered meaningful is subjective and conditional on several 
factors including costs, potential side effects and patient preferences. A comparison with benefit 
from other preventive treatments may contribute to the interpretation of treatment benefit from 
PCSK9-inhibition. For example, a microsimulation study on statin therapy in individuals without 
cardiovascular disease showed individualized benefits ranging from 4 to 18 months gain in 
cardiovascular event-free life expectancy.24 The patients in this microsimulation study were at 
relatively low cardiovascular risk (the majority had 10-year risk <20%). Compared with the 
subgroups at <20% 10-year risk in the present study, our findings are quite similar. Two recent 
studies evaluated the event-free months gained by aspirin treatment in the primary prevention 
setting and found small effects ranging from no gain to about 2 months estimated gain for an 
individual patient.18, 25 The small effect size is explained by the much lower relative risk reduction 
of aspirin therapy compared to lipid lowering therapy and the relatively low risk population that 
was studied. Similar to the present study, all these studies show that expected treatment benefits 
were highest in younger patients, in particular in the presence of cardiovascular risk factors. 
As with all interventions which reduce cardiovascular risk, the individual treatment effect of 
PCSK9-inhibition needs to be interpreted in the light of other (less costly) interventions for risk 
reduction, such as life style improvements. For example, smoking cessation may yield more 
individual lifetime benefit than lipid lowering, as this reduces both cardiovascular and non-
cardiovascular mortality. It is evident that such potential life style enhancements need to be taken 
into account on when considering to prescribe PCSK9-inhibition.  
16 
 
 
Initiating PCSK9-inhibition in relatively young patients is at the cost of longer treatment. The cost-
effectiveness of PCSK9-inhibition in patients with cardiovascular disease has been evaluated.26-28 
Although PCSK9-inhibition may on average be cost-effective, two studies concluded that to reach 
cost-effectiveness, the price of PCSK9-inhibitors would need to be reduced substantially. As there 
is great variation in LDL-C levels and cardiovascular risk among patients with cardiovascular 
disease (Supplemental Figure 1),29 a stratified cost-effectiveness analysis, for example for 
estimated 10-year risk, may help clarify in which patients the expected benefit of PCSK9-inhibition 
outweighs costs.  
 
Individualized estimation of treatment benefit can be used to inform the patient and contribute to 
shared decision making on whether or not initiating PCSK9-inhibition. A benefit-based approach 
may be adopted in future clinical guidelines for treating the right patient and not prescribing costly 
treatment to patients with no or limited expected benefit in terms of survival free of stroke or MI.11, 
12, 25, 30   
Our findings are generalizable to patients with stable CAD similar to the TNT trial population 
(Table 1). Importantly, as patients with severe comorbidity such as malignancy were excluded, our 
results apply to relatively healthy statin-treated patients with CAD, with low risk of non-
cardiovascular mortality. For patients with CAD with higher expected non-cardiovascular 
mortality risk, the expected benefit is likely to be somewhat lower as a competing event may 
prevent long-term benefit of PCSK9-inhibition. Also, patients with familial hypercholesterolemia 
or with statin intolerance were excluded. As LDL-C levels are likely to be higher in these 
populations, lifetime benefit may also be larger particularly in those at younger age and if several 
other risk factors are present.  
17 
 
 
Strengths of this study are the relevant study population, as well as the individualized benefit 
approach from a lifetime perspective with adjustments for competing non-cardiovascular mortality. 
We acknowledge study limitations. Firstly, PCSK9-inhibition is likely to reduce the risk of both 
the recurrent event and subsequent events. As a result, disregarding subsequent events may result 
in an underestimation of the effect of this preventive treatment. A second limitation is that the 
effect of LDL-C reduction on cardiovascular events was extrapolated from meta-analyses (HR 0.79 
per mmol/L (39 mg/dL) LDL-C reduction) to patients that already had relatively low LDL-C levels 
(<1.8 mmol/L (<70 mg/dL)). Since the effect of LDL-C lowering has been shown to be very robust 
across several subgroups, including lipid subgroups, we think it is unlikely that the effect in lower 
LDL-C ranges will differ greatly from this estimate.8, 31 Nevertheless, future research in patients 
within lower LDL-C ranges is necessary as we show that in some patients LDL-C lowering may 
result in substantial benefit even if LDL-C levels are below 1.8 mmol/L (70 mg/dL) (Table 3). 
Finally, the lifetime estimates go beyond the 4 years of follow-up as observed in the study 
population. In a previous study it was shown that lifetime predictions based on the applied methods 
are valid for survival up to 17 years.18 Nevertheless, it could be argued that longer term validation 
is desirable. 
 
In conclusion, the potential incremental benefit of PCSK9-inhibition varies greatly amongst 
patients with stable CAD on high-dose statin treatment, ranging from a few months to more than a 
year gain in life expectancy free of (recurrent) stroke or MI. In general, most benefit can be 
achieved in middle aged patients (aged 40-60) with relatively high levels of LDL-C and other risk 
factors. Treatment benefit is expected to be limited in patients ≥70 years, in particular if LDL-C 
18 
 
levels are low. Individualized estimations of treatment benefit may contribute to targeted treatment 
and shared-decision making on whether or not initiating PCSK9-inhibition in statin-treated patients 
with stable CAD. 
  
19 
 
Funding 
This work was supported by ZonMw, the Netherlands Organization for Health Research and 
Development [grant number 836011027]. The TNT trial was sponsored by Pfizer. For the present 
study, the supporting sources had no involvement in study design, analysis, interpretation and 
writing of the results and decision to submit the report for publication. 
 
Disclosures 
L.K. declares no conflict of interest. 
K.K.R. reports in the past year research grants to Institution: Pfizer, Amgen, MSD, Sanofi, and 
Regeneron and consulting for Aegerion, Amgen, Astra Zeneca, Boehringer Ingelheim, Cerenis, 
Eli Lilly, Kowa, Merck, Pfizer, Regeneron, Resverlogix, Sanofi, and Takeda.  
S.M.B. declares receiving consultancy fees from Pfizer. 
Y.S. declares no conflict of interest. 
J.C. LaRosa declares consulting fees from Pfizer, Merck, Bristol-Myers Squibb and AstraZeneca 
and lecture fees from Pfizer. 
J.J.P.K. declares that he has acted as a consultant to and received honoraria from the following 
companies: Amgen, AstraZeneca, Boehringer Ingelheim, Catabasis, Cerenis, CSL Behring, 
Dezima Pharmaceuticals, Eli Lilly, Esperion, Isis, Merck, Novartis, Pronova, Regeneron, Sanofi, 
The Medicines Company, Kowa, Gemfire, Cymabay and Roche. 
Y.G. declares no conflict of interest 
20 
 
J.A.N.D. declares no conflict of interest. 
F.L.J.V. declares no conflict of interest. 
 
The Corresponding Author has the right to grant on behalf of all authors and does grant on 
behalf of all authors, an exclusive licence on a worldwide basis to the BMJ Publishing Group Ltd 
and its Licensees to permit this article (if accepted) to be published in HEART editions and any 
other BMJPGL products to exploit all subsidiary rights.  
21 
 
References 
1. Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania 
P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated 
with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 
2012;125:1979-1987. 
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra 
U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochen ML, Lollgen H, Marques-Vidal 
P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, Bart van der Worp H, 
van Dis I, Verschuren WM. 2016 European Guidelines on cardiovascular disease prevention in 
clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other 
Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives 
of 10 societies and by invited experts) Developed with the special contribution of the European 
Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 
2016;252:207-274. 
3. Smith SC, Jr., Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons 
RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, 
Sacco RL, Spertus J, Stein JH, Taubert KA. AHA/ACCF secondary prevention and risk reduction 
therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a 
guideline from the American Heart Association and American College of Cardiology Foundation 
endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J 
Am Coll Cardiol. 2011;58:2432-2446. 
4. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, 
Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR. Fourier Steering Committee 
Investigators. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl 
J Med. 2017:1713-1722. 
5. Simoons ML, Deckers JW. Intensive LDL lowering therapy for prevention of recurrent 
cardiovascular events: a word of caution. Eur Heart J. 2016;37:520-523. 
6. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, 
Kandzari DE, Kubica JM, D'Agostino RB, Sr., Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm 
M. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With 
Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163:40-51. 
7. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis 
BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, 
Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM. Improve-It Investigators. 
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 
2015;372:2387-2397. 
8. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, 
Peto R, Collins R, Simes R. Cholesterol Treatment Trialists Collaborators. Efficacy and safety of 
cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 
randomised trials of statins. Lancet. 2005;366:1267-1278. 
9. Dorresteijn JA, Visseren FL, Wassink AM, Gondrie MJ, Steyerberg EW, Ridker PM, Cook 
NR, van der Graaf Y. Development and validation of a prediction rule for recurrent vascular events 
based on a cohort study of patients with arterial disease: the SMART risk score. Heart. 
2013;99:866-872. 
10. Wilson PWF, D'Agostino R, Bhatt DL, Eagle K, Pencina MJ, Smith SC, Alberts MJ, 
Dallongeville J, Goto S, Hirsch AT, Liau CS, Ohman EM, Rother J, Reid C, Mas JL, Steg G. Reach 
22 
 
Registry. An International Model to Predict Recurrent Cardiovascular Disease. Am J Med. 
2012;125:695-703. 
11. Robinson JG, Ray K. Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not 
Needed in Lipid Treatment Guidelines. Arterioscler Thromb Vasc Biol. 2016;36:586-590. 
12. Robinson JG, Ray K. Moving Toward the Next Paradigm for Cardiovascular Prevention. 
Circulation. 2016;133:1533-1536. 
13. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, 
Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets I. Intensive lipid lowering with 
atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435. 
14. Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C, Members 
TNTSC, Investigators. Treating to New Targets (TNT) Study: does lowering low-density 
lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical 
benefit? Am J Cardiol. 2004;93:154-158. 
15. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to 
imputation of missing values. J Clin Epidemiol. 2006;59:1087-1091. 
16. Soran H, Schofield JD, Durrington PN. Cholesterol, not just cardiovascular risk, is 
important in deciding who should receive statin treatment. Eur Heart J. 2015;36:2975-2983. 
17. Shapiro MD, Fazio S, Tavori H. Targeting PCSK9 for therapeutic gains. Curr Atheroscler 
Rep. 2015;17:499. 
18. Dorresteijn JA, Kaasenbrood L, Cook NR, van Kruijsdijk RC, van der Graaf Y, Visseren 
FL, Ridker PM. How to translate clinical trial results into gain in healthy life expectancy for 
individual patients. BMJ. 2016;352:i1548. 
19. Hippisley-Cox J, Coupland C, Robson J, Brindle P. Derivation, validation, and evaluation 
of a new QRISK model to estimate lifetime risk of cardiovascular disease: cohort study using 
QResearch database. BMJ. 2010;341:c6624. 
20. E. S. Clinical prediction models: a practical approach to development, validation, and 
updating. New York: Springer; 2009. 
21. Morrone D, Weintraub WS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec 
AM. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of 
factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 
clinical trials. Atherosclerosis. 2012;223:251-261. 
22. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Jr., Hoffman E, Goto S, Ohman 
EM, Bhatt DL. Reduction of Atherothrombosis for Continued Health Registry Investigators. 
Adherence to secondary prevention medications and four-year outcomes in outpatients with 
atherosclerosis. Am J Med. 2013;126:693-700 e691. 
23. Sniderman AD, Thanassoulis G, Williams K, Pencina M. Risk of Premature Cardiovascular 
Disease vs the Number of Premature Cardiovascular Events. JAMA Cardiol. 2016;1:492-494. 
24. Ferket BS, van Kempen BJ, Heeringa J, Spronk S, Fleischmann KE, Nijhuis RL, Hofman 
A, Steyerberg EW, Hunink MG. Personalized prediction of lifetime benefits with statin therapy for 
asymptomatic individuals: a modeling study. PLoS Med. 2012;9:e1001361. 
25. Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP. Aspirin for the 
Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the 
U.S. Preventive Services Task Force. Ann Intern Med. 2016. 
26. Gandra SR, Villa G, Fonarow GC, Lothgren M, Lindgren P, Somaratne R, van Hout B. 
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular 
Risk in the United States. Clin Cardiol. 2016;39:313-320. 
23 
 
27. Tice JA, Kazi DS, Pearson SD. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) 
Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value. JAMA Intern Med. 
2016;176:107-108. 
28. Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, Tice JA, Guzman 
D, Bibbins-Domingo K. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With 
Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA. 
2016;316:743-753. 
29. Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJ, Kastelein JJ, 
Amarenco P, LaRosa JC, Cramer MJ, Westerink J, Kappelle LJ, de Borst GJ, Visseren FL. 
Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a 
Secondary Prevention Population. Circulation. 2016;134:1419-1429. 
30. Thanassoulis G, Williams K, Altobelli KK, Pencina MJ, Cannon CP, Sniderman AD. 
Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of 
Cardiovascular Disease. Circulation. 2016;133:1574-1581. 
31. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith 
C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive 
lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised 
trials. Lancet. 2010;376:1670-1681. 
 
  
24 
 
Figure legends 
 
Figure 1. Distribution of estimated individual lifetime benefit from PCSK9-inhibition (in 
months free of stroke or MI) in stable CAD patients treated with high-dose statin 
 
Figure 2. Individual patient illustrations of estimated benefit from PCSK9-inhibition 
(months gain free of stroke or MI) 
